195 related articles for article (PubMed ID: 26010511)
61. Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period.
Spearman P; Tomaras GD; Montefiori DC; Huang Y; Elizaga ML; Ferrari G; Alam SM; Isaacs A; Ahmed H; Hural J; McElrath MJ; Ouedraogo L; Pensiero M; Butler C; Kalams SA; Overton ET; Barnett SW;
J Infect Dis; 2019 May; 219(11):1755-1765. PubMed ID: 30615119
[TBL] [Abstract][Full Text] [Related]
62. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.
Chen Y; Wilson R; O'Dell S; Guenaga J; Feng Y; Tran K; Chiang CI; Arendt HE; DeStefano J; Mascola JR; Wyatt RT; Li Y
J Immunol; 2016 Nov; 197(10):3982-3998. PubMed ID: 27815444
[TBL] [Abstract][Full Text] [Related]
63. A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies.
Calado R; Duarte J; Borrego P; Marcelino JM; Bártolo I; Martin F; Figueiredo I; Almeida S; Graça L; Vítor J; Aires da Silva F; Dias I; Carrapiço B; Taveira N
Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32272637
[TBL] [Abstract][Full Text] [Related]
64. Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate.
Visciano ML; Tagliamonte M; Stewart-Jones G; Heyndrickx L; Vanham G; Jansson M; Fomsgaard A; Grevstad B; Ramaswamy M; Buonaguro FM; Tornesello ML; Biswas P; Scarlatti G; Buonaguro L;
J Transl Med; 2013 Jul; 11():165. PubMed ID: 23835244
[TBL] [Abstract][Full Text] [Related]
65. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen.
Zhang MY; Wang Y; Mankowski MK; Ptak RG; Dimitrov DS
Vaccine; 2009 Feb; 27(6):857-63. PubMed ID: 19084043
[TBL] [Abstract][Full Text] [Related]
66. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.
Bianchi E; Joyce JG; Miller MD; Finnefrock AC; Liang X; Finotto M; Ingallinella P; McKenna P; Citron M; Ottinger E; Hepler RW; Hrin R; Nahas D; Wu C; Montefiori D; Shiver JW; Pessi A; Kim PS
Proc Natl Acad Sci U S A; 2010 Jun; 107(23):10655-60. PubMed ID: 20483992
[TBL] [Abstract][Full Text] [Related]
67. Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.
Rosenberg Y; Sack M; Montefiori D; Labranche C; Lewis M; Urban L; Mao L; Fischer R; Jiang X
PLoS One; 2015; 10(3):e0120451. PubMed ID: 25807114
[TBL] [Abstract][Full Text] [Related]
68. Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity.
Prigent J; Jarossay A; Planchais C; Eden C; Dufloo J; Kök A; Lorin V; Vratskikh O; Couderc T; Bruel T; Schwartz O; Seaman MS; Ohlenschläger O; Dimitrov JD; Mouquet H
Cell Rep; 2018 May; 23(9):2568-2581. PubMed ID: 29847789
[TBL] [Abstract][Full Text] [Related]
69. The Antibody Germline/Maturation Hypothesis, Elicitation of Broadly Neutralizing Antibodies Against HIV-1 and Cord Blood IgM Repertoires.
Prabakaran P; Chen W; Dimitrov DS
Front Immunol; 2014; 5():398. PubMed ID: 25221552
[TBL] [Abstract][Full Text] [Related]
70. HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors.
Lin YR; Parks KR; Weidle C; Naidu AS; Khechaduri A; Riker AO; Takushi B; Chun JH; Borst AJ; Veesler D; Stuart A; Agrawal P; Gray M; Pancera M; Huang PS; Stamatatos L
Immunity; 2020 Oct; 53(4):840-851.e6. PubMed ID: 33053332
[TBL] [Abstract][Full Text] [Related]
71. Broad antibody mediated cross-neutralization and preclinical immunogenicity of new codon-optimized HIV-1 clade CRF02_AG and G primary isolates.
Agwale SM; Forbi JC; Notka F; Wrin T; Wild J; Wagner R; Wolf H
PLoS One; 2011; 6(8):e23233. PubMed ID: 21829720
[TBL] [Abstract][Full Text] [Related]
72. Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.
Dosenovic P; von Boehmer L; Escolano A; Jardine J; Freund NT; Gitlin AD; McGuire AT; Kulp DW; Oliveira T; Scharf L; Pietzsch J; Gray MD; Cupo A; van Gils MJ; Yao KH; Liu C; Gazumyan A; Seaman MS; Björkman PJ; Sanders RW; Moore JP; Stamatatos L; Schief WR; Nussenzweig MC
Cell; 2015 Jun; 161(7):1505-15. PubMed ID: 26091035
[TBL] [Abstract][Full Text] [Related]
73. Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity.
Goldberg BS; Kaku CI; Dufloo J; Bruel T; Schwartz O; Spencer DA; Hessell AJ; Ackerman ME
mBio; 2021 Oct; 12(5):e0174321. PubMed ID: 34634936
[TBL] [Abstract][Full Text] [Related]
74. Early development of broadly neutralizing antibodies in HIV-1-infected infants.
Goo L; Chohan V; Nduati R; Overbaugh J
Nat Med; 2014 Jun; 20(6):655-8. PubMed ID: 24859529
[TBL] [Abstract][Full Text] [Related]
75. Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows.
Sok D; Le KM; Vadnais M; Saye-Francisco KL; Jardine JG; Torres JL; Berndsen ZT; Kong L; Stanfield R; Ruiz J; Ramos A; Liang CH; Chen PL; Criscitiello MF; Mwangi W; Wilson IA; Ward AB; Smider VV; Burton DR
Nature; 2017 Aug; 548(7665):108-111. PubMed ID: 28726771
[TBL] [Abstract][Full Text] [Related]
76. Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies.
Sun Z; Yan L; Tang J; Qian Q; Lenberg J; Zhu D; Liu W; Wu K; Wang Y; Lu S
Virus Res; 2018 Jan; 243():75-82. PubMed ID: 29051051
[TBL] [Abstract][Full Text] [Related]
77. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice.
Sok D; Briney B; Jardine JG; Kulp DW; Menis S; Pauthner M; Wood A; Lee EC; Le KM; Jones M; Ramos A; Kalyuzhniy O; Adachi Y; Kubitz M; MacPherson S; Bradley A; Friedrich GA; Schief WR; Burton DR
Science; 2016 Sep; 353(6307):1557-1560. PubMed ID: 27608668
[TBL] [Abstract][Full Text] [Related]
78. Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.
Sneha Priya R; Veena M; Kalisz I; Whitney S; Priyanka D; LaBranche CC; Sri Teja M; Montefiori DC; Pal R; Mahalingam S; Kalyanaraman VS
J Biol Chem; 2015 Apr; 290(14):9195-208. PubMed ID: 25691567
[TBL] [Abstract][Full Text] [Related]
79. High throughput analysis of B cell dynamics and neutralizing antibody development during immunization with a novel clade C HIV-1 envelope.
Mopuri R; Welbourn S; Charles T; Ralli-Jain P; Rosales D; Burton S; Aftab A; Karunakaran K; Pellegrini K; Kilembe W; Karita E; Gnanakaran S; Upadhyay AA; Bosinger SE; Derdeyn CA
PLoS Pathog; 2023 Oct; 19(10):e1011717. PubMed ID: 37878666
[TBL] [Abstract][Full Text] [Related]
80. Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.
Verkoczy L; Diaz M
Curr Opin HIV AIDS; 2014 May; 9(3):224-34. PubMed ID: 24714565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
